Immunomedics Creates Novel Antibody-cytokine Conjugates for Cancer Therapy
نویسنده
چکیده
Washington, DC, April 8, 2013 --Immunomedics, Inc. (Nasdaq: IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibodybased products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced the creation of a new class of antibody-cytokine conjugates using the Company’s patented DOCK-AND-LOCKTM (DNLTM) platform technology. These DNLTM complexes demonstrated potent anti-tumor activity in preclinical studies.
منابع مشابه
Immunomedics Awarded U.s. Patent for Novel Immuno- Oncology Agents for Cancer Therapy
The new invention concerns methods of use of T-cell redirecting bispecific antibodies, created with the Company’s proprietary DOCK-AND-LOCK (DNL) protein conjugation platform technology. The issued claims cover use of DNL complexes that simultaneously bind to the CD3 T-cell antigen and the Trop-2 tumor antigen, which is expressed by many solid cancers. The claims specifically cover use of the C...
متن کاملPreclinical Study on Enhancing Sacituzumab Govitecan (immu-132) Activity in Sn-38-resistant Cancer Cells Published
Morris Plains, NJ, August 18, 2016 --Immunomedics, Inc. (Nasdaq: IMMU) today announced that adding an inhibitor of ATP-binding cassette (ABC) transporters to sacituzumab govitecan, the Company’s lead antibody-drug conjugate (ADC) for solid cancer therapy, increased the median survival of mice bearing a SN-38-resistant human gastric cancer cell line. Results from this preclinical study were publ...
متن کاملCancer Therapy: Preclinical CEACAM5-Targeted Therapy of Human Colonic and Pancreatic Cancer Xenografts with Potent Labetuzumab-SN-38 Immunoconjugates
Purpose: To improve the efficacy and reduce the gastrointestinal toxicity of the cancer prodrug, CPT-11, we have developed immunoconjugates of its active form, SN-38, and an anti-CEACAM5 antibody for targeted chemotherapy. Experimental Design: SN-38 conjugates of the anti-CEACAM5 monoclonal antibody, labetuzumab (hMN-14), varying in the nature of the cross-linker attachment at the drug's 20-hyd...
متن کاملAntibody-based delivery of IL2 and cytotoxics eradicates tumors in immunocompetent mice.
Antibody-drug conjugates are increasingly being used for cancer therapy, but little is known about their ability to promote anticancer immunity, which may lead to long-lasting remissions. We investigated the therapeutic effect of antibody-based pharmacodelivery of cemadotin, a cytotoxic drug, and IL2, a strong proinflammatory cytokine. Using the F8 antibody, which selectively localizes to the t...
متن کاملDesign, synthesis and biological evaluation of Ciprofloxacin- peptide conjugates as anticancer agents
Cancer has emerged as a leading cause of death throughout the world. Peptides are a novel class of anticancer agents that can specifically target cancer cells with low toxicity to normal tissues and thus, offer new opportunities for future cancer treatment. On the other hand, Ciprofloxacin, an antibiotic, also known to its anticancer property for enabling cell cycle arrest and creating double s...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2013